SEHK:3933Pharmaceuticals
Assessing United Laboratories International Holdings (SEHK:3933) Valuation After Dupilumab Biosimilar Trial Approval
Clinical trial approval and what it means for investors
United Laboratories International Holdings (SEHK:3933) has drawn fresh attention after regulators in China approved the clinical trial application for its dupilumab biosimilar targeting atopic dermatitis, a step that highlights progress in its autoimmune pipeline.
See our latest analysis for United Laboratories International Holdings.
The share price has recently picked up, with a 1-day share price return of 2.77% taking the stock to...